Purpose: Obstructive sleep apnea (OSA) is associated with altered pairwise connections between brain regions, which might explain cognitive impairment and daytime sleepiness. By adopting a deep learning method, we investigated brain connectivity related to the severity of OSA and daytime sleepiness.
Patients And Methods: A cross-sectional design applied a deep learning model on structural brain networks obtained from 553 subjects (age, 59.2 ± 7.4 years; men, 35.6%). The model performance was evaluated with the Pearson's correlation coefficient () and probability of absolute error less than standard deviation (P) between the estimated and the actual scores. In addition, we investigated sex effects on deep learning outputs for OSA and daytime sleepiness and examined the differences in brain connectivity related to daytime sleepiness between OSA and non-OSA groups.
Results: We achieved a meaningful (up to 0.74) and P (up to 0.92) in a test dataset of whole group and subgroups. Motor, frontal and limbic areas, and default mode network were the prominent hubs of important connectivity to predict OSA severity and daytime sleepiness. Sex affected brain connectivity relevant to OSA severity as well as daytime sleepiness. Brain connectivity associated with daytime sleepiness also differed by the presence vs absence of OSA.
Conclusion: A deep learning method can assess the association of brain network characteristics with OSA severity and daytime sleepiness and specify the relevant brain connectivity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455296 | PMC |
http://dx.doi.org/10.2147/NSS.S327110 | DOI Listing |
Crit Care
January 2025
Department of Intensive Care Unit, The First Hospital of China Medical University, Shenyang, China.
Background: The role that sleep patterns play in sepsis risk remains poorly understood.
Objectives: The objective was to evaluate the association between various sleep behaviours and the incidence of sepsis.
Methods: In this prospective cohort study, we analysed data from the UK Biobank (UKB).
Mol Psychiatry
January 2025
Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, 08854, USA.
The hypothalamic neuropeptide system of orexin (hypocretin) neurons provides projections throughout the neuraxis and has been linked to sleep regulation, feeding and motivation for salient rewards including drugs of abuse. However, relatively little has been done to examine genes associated with orexin signaling and specific behavioral phenotypes in humans. Here, we tested for association of twenty-seven genes involved in orexin signaling with behavioral phenotypes in humans.
View Article and Find Full Text PDFInt J Occup Saf Ergon
January 2025
Faculty of Nursing, Atatürk University, Turkey.
This study aimed to investigate the relationship between nurses' Internet addiction, sleep quality and sleepiness. Research data were collected with an online and face-to-face introduction form, the Internet addiction scale (IAS), the Pittsburgh sleep quality index (PSQI) and the Epworth sleepiness scale (ESS) between January and April 2022. In data analysis, descriptive statistics, correlation and multiple regression analysis were performed.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Obstructive sleep apnea (OSA) patients have varying degrees of cognitive impairment, but the specific pathogenic mechanism is still unclear. Meanwhile, poor compliance with continuous positive airway pressure (CPAP) in OSA prompts better solutions. This study aimed to identify differentially expressed genes between the non-obese OSA patients and healthy controls, and to explore potential biomarkers associated with cognitive impairment.
View Article and Find Full Text PDFPaediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!